Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications

Yoshihiko Segawa, Saburo Takata, Masanori Fujii, Isao Oze, Yoshiro Fujiwara, Yuka Kato, Atsuko Ogino, Eisaku Komori, Shigeki Sawada, Motohiro Yamashita, Rieko Nishimura, Norihiro Teramoto, Shigemitsu Takashima

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to prospectively assess the clinical implications of neuroendocrine (NE) differentiation in non-small-cell lung cancer (NSCLC) tumors. Methods: This study accrued subjects suspected to have lung cancer who underwent diagnostic bronchoscopy. Bronchoscopically-biopsied specimens were subjected to routine pathologic examination, and immunohistochemical studies were then performed if lung cancer was diagnosed. Chromogranin-A, synaptophysin, neural cell adhesion molecule, and Leu7 were used to demonstrate NE differentiation. Results: A total of 280 subjects were accrued to this study over a period of 2 years. Among them, 149 subjects were assessable for this study, and 130 were diagnosed as having NSCLC tumors (55 adenocarcinomas, 50 squamous cell carcinomas, 24 NSCLCs not otherwise specified, and 1 typical carcinoid). Large cell NE carcinoma was not observed in this study. Immunohistochemically, NE differentiation was detected in 16% of NSCLC tumors excluding typical carcinoid. By status of NE differentiation of NSCLC tumors, progression-free survivals were similar in 73 patients undergoing non-surgical treatment (positive, n = 10; negative, n = 63) and 43 patients undergoing surgical resection (positive, n = 8; negative, n = 35), respectively. Overall survival of patients with NE-positive tumors appeared to be favorable both for those undergoing non-surgical treatment and those undergoing surgical resection, though the differences in survival were not significant (P = 0.11 and 0.35, respectively). Conclusions: NE differentiation was detected in 16% of NSCLC tumors in our study. However, the prognostic implications of the presence of this feature could not be clearly determined in this study.

Original languageEnglish
Pages (from-to)1055-1059
Number of pages5
JournalJournal of Cancer Research and Clinical Oncology
Volume135
Issue number8
DOIs
Publication statusPublished - Aug 2009

Fingerprint

Non-Small Cell Lung Carcinoma
Carcinoid Tumor
Neoplasms
Lung Neoplasms
Neuroendocrine Carcinoma
Large Cell Carcinoma
Neural Cell Adhesion Molecules
Chromogranin A
Synaptophysin
Survival
Neuroendocrine Tumors
Bronchoscopy
Disease-Free Survival
Squamous Cell Carcinoma
Adenocarcinoma
Therapeutics

Keywords

  • Immunohistochemistry
  • Neuroendocrine differentiation
  • Neuroendocrine lung tumor
  • Non-small-cell lung carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications. / Segawa, Yoshihiko; Takata, Saburo; Fujii, Masanori; Oze, Isao; Fujiwara, Yoshiro; Kato, Yuka; Ogino, Atsuko; Komori, Eisaku; Sawada, Shigeki; Yamashita, Motohiro; Nishimura, Rieko; Teramoto, Norihiro; Takashima, Shigemitsu.

In: Journal of Cancer Research and Clinical Oncology, Vol. 135, No. 8, 08.2009, p. 1055-1059.

Research output: Contribution to journalArticle

Segawa, Y, Takata, S, Fujii, M, Oze, I, Fujiwara, Y, Kato, Y, Ogino, A, Komori, E, Sawada, S, Yamashita, M, Nishimura, R, Teramoto, N & Takashima, S 2009, 'Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications', Journal of Cancer Research and Clinical Oncology, vol. 135, no. 8, pp. 1055-1059. https://doi.org/10.1007/s00432-009-0544-1
Segawa, Yoshihiko ; Takata, Saburo ; Fujii, Masanori ; Oze, Isao ; Fujiwara, Yoshiro ; Kato, Yuka ; Ogino, Atsuko ; Komori, Eisaku ; Sawada, Shigeki ; Yamashita, Motohiro ; Nishimura, Rieko ; Teramoto, Norihiro ; Takashima, Shigemitsu. / Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications. In: Journal of Cancer Research and Clinical Oncology. 2009 ; Vol. 135, No. 8. pp. 1055-1059.
@article{4f2789757432469baa0511cc9cfcc09a,
title = "Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications",
abstract = "Purpose: The purpose of this study was to prospectively assess the clinical implications of neuroendocrine (NE) differentiation in non-small-cell lung cancer (NSCLC) tumors. Methods: This study accrued subjects suspected to have lung cancer who underwent diagnostic bronchoscopy. Bronchoscopically-biopsied specimens were subjected to routine pathologic examination, and immunohistochemical studies were then performed if lung cancer was diagnosed. Chromogranin-A, synaptophysin, neural cell adhesion molecule, and Leu7 were used to demonstrate NE differentiation. Results: A total of 280 subjects were accrued to this study over a period of 2 years. Among them, 149 subjects were assessable for this study, and 130 were diagnosed as having NSCLC tumors (55 adenocarcinomas, 50 squamous cell carcinomas, 24 NSCLCs not otherwise specified, and 1 typical carcinoid). Large cell NE carcinoma was not observed in this study. Immunohistochemically, NE differentiation was detected in 16{\%} of NSCLC tumors excluding typical carcinoid. By status of NE differentiation of NSCLC tumors, progression-free survivals were similar in 73 patients undergoing non-surgical treatment (positive, n = 10; negative, n = 63) and 43 patients undergoing surgical resection (positive, n = 8; negative, n = 35), respectively. Overall survival of patients with NE-positive tumors appeared to be favorable both for those undergoing non-surgical treatment and those undergoing surgical resection, though the differences in survival were not significant (P = 0.11 and 0.35, respectively). Conclusions: NE differentiation was detected in 16{\%} of NSCLC tumors in our study. However, the prognostic implications of the presence of this feature could not be clearly determined in this study.",
keywords = "Immunohistochemistry, Neuroendocrine differentiation, Neuroendocrine lung tumor, Non-small-cell lung carcinoma",
author = "Yoshihiko Segawa and Saburo Takata and Masanori Fujii and Isao Oze and Yoshiro Fujiwara and Yuka Kato and Atsuko Ogino and Eisaku Komori and Shigeki Sawada and Motohiro Yamashita and Rieko Nishimura and Norihiro Teramoto and Shigemitsu Takashima",
year = "2009",
month = "8",
doi = "10.1007/s00432-009-0544-1",
language = "English",
volume = "135",
pages = "1055--1059",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications

AU - Segawa, Yoshihiko

AU - Takata, Saburo

AU - Fujii, Masanori

AU - Oze, Isao

AU - Fujiwara, Yoshiro

AU - Kato, Yuka

AU - Ogino, Atsuko

AU - Komori, Eisaku

AU - Sawada, Shigeki

AU - Yamashita, Motohiro

AU - Nishimura, Rieko

AU - Teramoto, Norihiro

AU - Takashima, Shigemitsu

PY - 2009/8

Y1 - 2009/8

N2 - Purpose: The purpose of this study was to prospectively assess the clinical implications of neuroendocrine (NE) differentiation in non-small-cell lung cancer (NSCLC) tumors. Methods: This study accrued subjects suspected to have lung cancer who underwent diagnostic bronchoscopy. Bronchoscopically-biopsied specimens were subjected to routine pathologic examination, and immunohistochemical studies were then performed if lung cancer was diagnosed. Chromogranin-A, synaptophysin, neural cell adhesion molecule, and Leu7 were used to demonstrate NE differentiation. Results: A total of 280 subjects were accrued to this study over a period of 2 years. Among them, 149 subjects were assessable for this study, and 130 were diagnosed as having NSCLC tumors (55 adenocarcinomas, 50 squamous cell carcinomas, 24 NSCLCs not otherwise specified, and 1 typical carcinoid). Large cell NE carcinoma was not observed in this study. Immunohistochemically, NE differentiation was detected in 16% of NSCLC tumors excluding typical carcinoid. By status of NE differentiation of NSCLC tumors, progression-free survivals were similar in 73 patients undergoing non-surgical treatment (positive, n = 10; negative, n = 63) and 43 patients undergoing surgical resection (positive, n = 8; negative, n = 35), respectively. Overall survival of patients with NE-positive tumors appeared to be favorable both for those undergoing non-surgical treatment and those undergoing surgical resection, though the differences in survival were not significant (P = 0.11 and 0.35, respectively). Conclusions: NE differentiation was detected in 16% of NSCLC tumors in our study. However, the prognostic implications of the presence of this feature could not be clearly determined in this study.

AB - Purpose: The purpose of this study was to prospectively assess the clinical implications of neuroendocrine (NE) differentiation in non-small-cell lung cancer (NSCLC) tumors. Methods: This study accrued subjects suspected to have lung cancer who underwent diagnostic bronchoscopy. Bronchoscopically-biopsied specimens were subjected to routine pathologic examination, and immunohistochemical studies were then performed if lung cancer was diagnosed. Chromogranin-A, synaptophysin, neural cell adhesion molecule, and Leu7 were used to demonstrate NE differentiation. Results: A total of 280 subjects were accrued to this study over a period of 2 years. Among them, 149 subjects were assessable for this study, and 130 were diagnosed as having NSCLC tumors (55 adenocarcinomas, 50 squamous cell carcinomas, 24 NSCLCs not otherwise specified, and 1 typical carcinoid). Large cell NE carcinoma was not observed in this study. Immunohistochemically, NE differentiation was detected in 16% of NSCLC tumors excluding typical carcinoid. By status of NE differentiation of NSCLC tumors, progression-free survivals were similar in 73 patients undergoing non-surgical treatment (positive, n = 10; negative, n = 63) and 43 patients undergoing surgical resection (positive, n = 8; negative, n = 35), respectively. Overall survival of patients with NE-positive tumors appeared to be favorable both for those undergoing non-surgical treatment and those undergoing surgical resection, though the differences in survival were not significant (P = 0.11 and 0.35, respectively). Conclusions: NE differentiation was detected in 16% of NSCLC tumors in our study. However, the prognostic implications of the presence of this feature could not be clearly determined in this study.

KW - Immunohistochemistry

KW - Neuroendocrine differentiation

KW - Neuroendocrine lung tumor

KW - Non-small-cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=68149108595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149108595&partnerID=8YFLogxK

U2 - 10.1007/s00432-009-0544-1

DO - 10.1007/s00432-009-0544-1

M3 - Article

C2 - 19152002

AN - SCOPUS:68149108595

VL - 135

SP - 1055

EP - 1059

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 8

ER -